Related Articles
Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure
Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR‑TKIs in advanced non‑small‑cell lung cancer
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression